Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 5281-5290 Newer>

Chemistry World November 28, 2008 Hayley Birch	Drug detonates nitric oxide inside tuberculosis bacteria US and Singaporean scientists have discovered how a promising anti-tuberculosis drug, PA-824, triggers an explosive chain of events inside its target bacterial cells.
Chemistry World November 28, 2008 Matt Wilkinson	EU claims pharma delaying tactics cost 3 billion euros Pharmaceutical manufacturers have been criticised by the EU competition commission for slowing the entry of generic medicines to the market.
The Motley Fool November 28, 2008 Brian Orelli	Will Patients Reject This Injection? Wyeth and Progenics release good trial data, but will patients want their constipation drug?
The Motley Fool November 28, 2008 Brian Orelli	Bargain Stocks for Black Friday: Intuitive Surgical This is a company that's seen trailing-12-month revenue increase 59% year over year. No matter what you think of high-growth stocks, its 25 P/E is pretty darn cheap.
The Motley Fool November 28, 2008 Brian Orelli	The FDA's Killing Bug Killers Unfortunately for Johnson & Johnson and Swiss drugmaker Basilea Pharmaceutica, the FDA appears a little reluctant to take some of the data for the drugmakers' antibiotic ceftobiprole at face value.
Fast Company December 2008 Jennifer Vilaga	The Institute for OneWorld Health: Not-for-profit Drugmaking The Institute for OneWorld Health is on the verge of proving that its no-profit/no-loss model can work.
Fast Company December 2008 Jennifer Vilaga	HopeLab: Video Games for Health Cancer-afflicted teens often have a hard time sticking to their meds. So Pam Omidyar came up with a spoonful of new sugar: video games.
The Motley Fool November 26, 2008 Brian Orelli	Watson Gets Some Hand-Me-Downs Much like discount stores, generic-drug makers are in a cutthroat low-margin business, where "larger" almost always means "better."
The Motley Fool November 26, 2008 Brian Orelli	Teva and AstraZeneca's Drama Concludes Teva and AstraZeneca settle a lawsuit, but investors are still left in the dark.
The Motley Fool November 26, 2008 Brian Orelli	Abraxis Fires AstraZeneca, Gets Fired Up Buoyed by deep pockets filled with cash after it separated from its generic drug business, Abraxis Bioscience is moving into the deep end with the big boys.
<Older 5281-5290 Newer> Return to current articles.